Memorial Sloan-Kettering Cancer Center Library Memorial Sloan-Kettering Cancer Center  
 
Select Library Resources
 
Patients, Families
& Caregivers
LibGuides
Administrative Staff
MSK Author Tools & Resources
 
All Library Resources
 
Document Delivery
Electronic Resources
Databases & Other Resources
Synapse
Library Services
Training & Tutorials

Click here

Home Today's science sparks archives
 Today's science sparks archives - October 2009

Today's science sparks archives - October 2009

October 29, 2009

Memorial Sloan-Kettering's Marc Ladanyi and others want to use tumor genetic profiling to match lung cancer patients with the best drug.

Memorial Sloan-Kettering's Marc Ladanyi and others want to use tumor genetic profiling to match lung cancer patients with the best drug.

  • Kaiser J

  • Science.
    2009 Oct 9;326(5950):218-20.

October 28, 2009

Fig 5. Activity of MDV3100 in vitro (A) Localisation of YFP-tagged androgen receptor (AR) in LNCaP cells after treatment with indicated drugs.

Fig 5. Activity of MDV3100 in vitro (A) Localisation of YFP-tagged androgen receptor (AR) in LNCaP cells after treatment with indicated drugs.

  • Chen Y, Clegg NJ, Scher HI

  • Lancet Oncol.
    2009 Oct;10(10):981-91.

October 27, 2009

Fig 2. Biopsy specimens stained with H&E (top) or analyzed by immunohistochemistry (IHC) using an anti-KIT antibody (bottom) show little, if any, difference before and after 1 wk of sunitinib treatment.

Fig 2. Biopsy specimens stained with H&E (top) or analyzed by immunohistochemistry (IHC) using an anti-KIT antibody (bottom) show little, if any, difference before and after 1 wk of sunitinib treatment.

  • Demetri GD, Heinrich MC, Fletcher JA, Fletcher CD, Van den Abbeele AD, Corless CL, Antonescu CR, George S, Morgan JA, Chen MH, Bello CL, Huang X, Cohen DP, Baum CM, Maki RG

  • Clin Cancer Res.
    2009 Sep 15;15(18):5902-9.

October 26, 2009

Fig 1. A moderately dysplastic nevus. A, Side-transillumination. B, Cross-polarization. An automated boundary detection method was used to create the outline shown surrounding both images (black outlines).

Fig 1. A moderately dysplastic nevus. A, Side-transillumination. B, Cross-polarization. An automated boundary detection method was used to create the outline shown surrounding both images (black outlines)..

  • Terushkin V, Dusza SW, Mullani NA, Duvic M, Zouridakis G, Weinstock M, Drugge R, Prieto VG, Dhawan A, Terry C, Talpur R, Marghoob AA

  • Arch Dermatol.
    2009 Sep;145(9):1060-2.

October 23, 2009

Fig 3. A Model of piRNA Biogenesis.

Fig 3. A Model of piRNA Biogenesis.

  • Betel D, Sheridan R, Marks DS, Sander C

  • PLoS Comput Biol.
    2007 Nov;3(11):e222.

October 22, 2009

Fig 1. Conceptual model of patient satisfaction and quality of life in breast surgery patients.

Fig 1. Conceptual model of patient satisfaction and quality of life in breast surgery patients.

  • Klassen AF, Pusic AL, Scott A, Klok J, Cano SJ

  • BMC Womens Health.
    2009 May 1;9:11.

October 21, 2009

Fig 7. Loss of p21 rescues functional BM-derived tumor angiogenesis in Id1-/- mice.

Fig 7. Loss of p21 rescues functional BM-derived tumor angiogenesis in Id1-/- mice.

  • Ciarrocchi A, Jankovic V, Shaked Y, Nolan DJ, Mittal V, Kerbel RS, Nimer SD, Benezra R

  • PLoS One.
    2007 Dec 19;2(12):e1338.

October 20, 2009

Fig 5a. Immunofluorescence analysis of HIF-1a(?ODDD)/Fluc trafficking in the NIH3T3 reporter cell line.

Fig 5a. Immunofluorescence analysis of HIF-1a(?ODDD)/Fluc trafficking in the NIH3T3 reporter cell line.

  • Moroz E, Carlin S, Dyomina K, Burke S, Thaler HT, Blasberg R, Serganova I

  • PLoS One.
    2009;4(4):e5077.

October 19, 2009

Fig 1. Proposed model for the regulatory roles played by Hsp90 in AD progression.

Fig 1. Proposed model for the regulatory roles played by Hsp90 in AD progression.

  • Luo W, Rodina A, Chiosis G

  • BMC Neurosci.
    2008 Dec 3;9 Suppl 2:S7.

October 16, 2009

Fig. 1. A, genomic profiles of multiple tumors from case 7. Both tumors displayed matching amplification and losses. B, closely matching allelic changes for 8 chromosome arms. aCGH array segmentation for tumor A (top) and B (bottom) are shown. Paired tumors exhibit similar genomic alterations, suggesting the diagnosis of metastases.

Fig. 1. A, genomic profiles of multiple tumors from case 7. Both tumors displayed matching amplification and losses. B, closely matching allelic changes for 8 chromosome arms. aCGH array segmentation for tumor A (top) and B (bottom) are shown. Paired tumors exhibit similar genomic alterations, suggesting the diagnosis of metastases.

  • Girard N, Ostrovnaya I, Lau C, Park B, Ladanyi M, Finley D, Deshpande C, Rusch V, Orlow I, Travis WD, Pao W, Begg CB

  • Clin Cancer Res.
    2009 Aug 15;15(16):5184-90.

October 15, 2009

Fig 1a. CT shows a 6.6-cm left adrenal mass.

Fig 1a. CT shows a 6.6-cm left adrenal mass.

  • Shah MH, Varker KA, Collamore M, Zwiebel JA, Coit D, Kelsen D, Chung KY

  • Am J Clin Oncol.
    2009 Apr;32(2):174-79.

October 14, 2009

Fig 3. CTLA-4–/– T reg cell display diminished regulatory activity during in vitro suppressor assays.

Fig 3. CTLA-4–/– T reg cell display diminished regulatory activity during in vitro suppressor assays.

  • Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP

  • J Exp Med.
    2009 Aug 3;206(8):1717-25.

October 13, 2009

Fig 4 - ERG directly regulates CXCR4 and ADAMTS1.(c) CXCR4 siRNA knockdown demonstrates a significant reduction in cell migration in PC3 cells overexpressing ERG.

Fig 4 - ERG directly regulates CXCR4 and ADAMTS1.(c) CXCR4 siRNA knockdown demonstrates a significant reduction in cell migration in PC3 cells overexpressing ERG.

  • Carver BS, Tran J, Gopalan A, Chen Z, Shaikh S, Carracedo A, Alimonti A, Nardella C, Varmeh S, Scardino PT, Cordon-Cardo C, Gerald W, Pandolfi PP.

  • Nat Genet.
    2009 May;41(5):619-24.

October 12, 2009

Fig 1. Siz/PIAS E3 Ligase Family Members and Structure of the Siz1 Catalytic Domain.

Fig 1. Siz/PIAS E3 Ligase Family Members and Structure of the Siz1 Catalytic Domain.

  • Yunus AA, Lima CD.

  • Mol Cell.
    2009 Sep 11;35(5):669-82.

October 9, 2009

Figure 1. Difference between groups in predicted outcome of treatment choice by maximum benefit. Light gray lines indicate 95% confidence intervals.

Figure 1. Difference between groups in predicted outcome of treatment choice by maximum benefit. Light gray lines indicate 95% confidence intervals.

  • Vickers AJ, Elkin EB, Peele PB, Dickler M, Siminoff LA.

  • Med Decis Making.
    2009 Jul-Aug;29(4):461-7.

October 8, 2009

Fig 6. CD14+CD16– and not CD14+CD16+ monocytes suppress germination of conidia.

Fig 6. CD14+CD16– and not CD14+CD16+ monocytes suppress germination of conidia.

  • Serbina NV, Cherny M, Shi C, Bleau SA, Collins NH, Young JW, Pamer EG

  • J Immunol.
    2009 Aug 15;183(4):2678-87.

October 7, 2009

Fig 1. The Overall Structure of Mms21 in Complex with the Arm Region of Smc5.

Fig 1. The Overall Structure of Mms21 in Complex with the Arm Region of Smc5.

  • Duan X, Sarangi P, Liu X, Rangi GK, Zhao X, Ye H

  • Mol Cell.
    2009 Sep 11;35(5):657-68.

October 6, 2009

Fig 4. Effect of altered DC homeostasis on autoimmunity.

Fig 4. Effect of altered DC homeostasis on autoimmunity.

  • JDarrasse-Jèze G, Deroubaix S, Mouquet H, Victora GD, Eisenreich T, Yao KH, Masilamani RF, Dustin ML, Rudensky A, Liu K, Nussenzweig MC

  • J Exp Med.
    2009 Aug 31;206(9):1853-62.

October 5, 2009

Fig 3. Maximal reduction for indicator lesions (Response Evaluation Criteria in Solid Tumors classification) by EGFR and KRAS genotype.

Fig 3. Maximal reduction for indicator lesions (Response Evaluation Criteria in Solid Tumors classification) by EGFR and KRAS genotype.

  • Jackman DM, Miller VA, Cioffredi LA, Yeap BY, Jänne PA, Riely GJ, Ruiz MG, Giaccone G, Sequist LV, Johnson BE

  • Clin Cancer Res.
    2009 Aug 15;15(16):5267-73.

October 2, 2009

Fig 1. Posterior peripheral zone cancer (A) with TZ-LOOK morphology (B).

Fig 1. Posterior peripheral zone cancer (A) with TZ-LOOK morphology (B).

  • Haarer CF, Gopalan A, Tickoo SK, Scardino PT, Eastham JA, Reuter VE, Fine SW

  • J Urol.
    2009 Oct;182(4):1337-41.

October 1, 2009

Fig 1. Histological appearance of the recurrent tumor. A: Mature teratoma showing squamous epithelium lined cysts (Hematoxylin and Eosin stain at 40×).

Fig 1. Histological appearance of the recurrent tumor. A: Mature teratoma showing squamous epithelium lined cysts (Hematoxylin and Eosin stain at 40×).

  • Busse C, Nazeer T, Kanwar VS, Wolden S, LaQuaglia MP, Rosenblum M

  • Pediatr Blood Cancer.
    2009 Oct;53(4):680-1.
Content editor, Sarah Jewell
Last revised: October 30, 2009 9:13 AM EST
medlibr@mskcc.org
© 2006-10 Memorial Sloan-Kettering Cancer Center Library
 1275 York Avenue New York, NY 10065
212-639-7439
Sloan-Kettering Institute
Gerstner Sloan-Kettering Graduate School of Biomedical Sciences Send eMail		 Memorial Sloan-Kettering Cancer Center
Legal Disclaimer Send eMail
 

 
JavaScript disabled or chat unavailable.
LIVE CHAT HOURS:
M-F 10am-4pm